|
|
| (13 intermediate revisions by 3 users not shown) |
| Line 7: |
Line 7: |
| | <head> | | <head> |
| | | | |
| − | <script type="text/javascript" src="https://2020.igem.org/wiki/index.php?title=Template:CCU_Taiwan/JS/bootstrap&action=raw&ctype=text/javascript"</script> | + | <script type="text/javascript" src="https://2020.igem.org/wiki/index.php?title=Template:CCU_Taiwan/JS/bootstrap&action=raw&ctype=text/javascript"></script> |
| − | <script type="text/javascript" src="https://2020.igem.org/wiki/index.php?title=Template:CCU_Taiwan/JS/jQuery&action=raw&ctype=text/javascript"</script>
| + | |
| | <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> | | <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> |
| | | | |
| Line 31: |
Line 30: |
| | <section id="ove"> | | <section id="ove"> |
| | <h2>Overview</h2> | | <h2>Overview</h2> |
| − | <p></p> | + | <p>With linear array epitope technique, we have produced various length of tandem-repeated sequence, but we need the sequences which are long enough to ensure that we have enough productivity. The plasmids we used to express protein are pET-29a(+) and pET-29b(+), where T7 promoter and lac operator would be induced with IPTG. On the other hand, there are also 6X His tag on pET-29a(+) and pET-29b(+) to purify our target proteins. Furthermore, we produced E protein to do the binding affinity test and CLEC5A to be our control. |
| | + | Our parts are as follows:</p> |
| | </section> | | </section> |
| | <br> | | <br> |
| Line 100: |
Line 100: |
| | <tr> | | <tr> |
| | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648009" target="_blank">BBa_K3648009</a></td> | | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648009" target="_blank">BBa_K3648009</a></td> |
| − | <td>TRS-110R*7</td> | + | <td>Thrombin site</td> |
| | <td>16</td> | | <td>16</td> |
| | </tr> | | </tr> |
| Line 118: |
Line 118: |
| | <br> | | <br> |
| | <section id="com"> | | <section id="com"> |
| − | <h2Composite Parts</h2> | + | <h2>Composite Parts</h2> |
| | <table> | | <table> |
| | <tbody> | | <tbody> |
| Line 128: |
Line 128: |
| | <tr> | | <tr> |
| | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648003" target="_blank">BBa_K3648003</a></td> | | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648003" target="_blank">BBa_K3648003</a></td> |
| − | <td>pET29b(+)-CLEC5A</td> | + | <td>pET-29b(+)_CLEC5A</td> |
| | <td>655</td> | | <td>655</td> |
| | </tr> | | </tr> |
| | <tr> | | <tr> |
| | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648004" target="_blank">BBa_K3648004</a></td> | | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648004" target="_blank">BBa_K3648004</a></td> |
| − | <td>pET29A(+)-E protein</td> | + | <td>pET-29a(+)_E protein</td> |
| | <td>1687</td> | | <td>1687</td> |
| | </tr> | | </tr> |
| Line 148: |
Line 148: |
| | <tr> | | <tr> |
| | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648013" target="_blank">BBa_K3648013</a></td> | | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648013" target="_blank">BBa_K3648013</a></td> |
| − | <td>pET-29b(+)_TRS-151*7</td> | + | <td>pET-29b(+)_TRS-151*8</td> |
| | <td>414</td> | | <td>414</td> |
| | </tr> | | </tr> |
| | <tr> | | <tr> |
| | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648015" target="_blank">BBa_K3648015</a></td> | | <td><a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K3648015" target="_blank">BBa_K3648015</a></td> |
| − | <td>pET-29b(+)-TRS-151*7</td> | + | <td>pET-29b(+)_TRS-151*7</td> |
| | <td>384</td> | | <td>384</td> |
| | </tr> | | </tr> |
